CD274 and neoplasm: While PD-L1 expression and tumor mutational burden (TMB) guide ICI selection, up to 60% of patients exhibit innate or acquired resistance, underscoring the urgent need for biomarkers that dynamically reconcile microenvironmental plasticity with treatment outcomes [1,2].